clinical trial · NCT07247162
Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome
HypertensionHypercortisolemiaCushing SyndromeOsilodrostatPlacebo
brief summary
Osilodrostat has proven to be a safe and efficacious treatment for patients with CS. Demonstrating normalisation of hypercortisolaemia and in patients with hypertension and/or dysglycaemia clinically relevant and statistically significant reductions in blood pressure and glycaemia. This study aims at providing additional evidence on the safety, efficacy and appropriate dosing of osilodrostat in patients with CS, who have hypertension.
started
Aug 1, 2026
primary completion
May 1, 2028
completion
Jul 1, 2028
last updated
Dec 10, 2025
official title
A Double-blind, Randomised, 30-week Placebo-controlled Phase IV Study to Assess the Efficacy and Safety of Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol